Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Carbohydrate doai
Patent
1992-05-26
1995-08-15
Griffin, Ronald W.
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Carbohydrate doai
514851, 514853, 514854, 514855, 514888, A61K 912, A61K 3170
Patent
active
054419387
ABSTRACT:
A novel therapy for Pseudomonas aeruginosa infections, in particular in cystic fibrosis patients, is described. Macrophages provide the first line of defence in protecting the lung against bacterial infections. Nonetheless, Pseudomonas aeruginosa infections continue to be problematic in cystic fibrosis patients and are the leading cause of death in these patients. Previously, little was known regarding the factors which regulate the capacity of macrophages to mediate phagocytosis of Pseudomonas aeruginosa. The inventors have now shown that phagocytosis of nonopsonized Pseudomonas aeruginosa by macrophages is dependent upon the presence of glucose. They have also shown that the action of glucose is on the macrophage rather than the bacteria. Glucose therapy can therefore be used to prevent or combat Pseudomonas aeruginosa infections.
REFERENCES:
patent: 3794722 (1974-02-01), Taya
patent: 4017608 (1977-04-01), Gordon
patent: 4061490 (1977-12-01), Yukinaga et al.
patent: 4158052 (1979-06-01), Audibert et al.
patent: 4536398 (1985-08-01), Ito et al.
patent: 4668508 (1987-05-01), Grollier et al.
patent: 4826679 (1989-05-01), Roy
patent: 5095104 (1992-03-01), Gordon
patent: 5100647 (1992-03-01), Agus et al.
patent: 5157024 (1992-10-01), Gordon
The Merck Index, Tenth Edition, Windholz, Editor, Published by Merck & Co., Inc. Rathway, N.J., pp. 638, 639 & 819.
Speert, D. P. Pseudomonas Aeruginosa Infections in Patients with Cystic Fibrosis in The Natural Immune System, vol. 2, The Macrophage, pp. 217-263, C. E. Lewis and O'D. McGee, Editors, Oxford University Press, 1992.
Michl, J., D. J. Ohlbaum, and S. C. Silverstein, 1976, 2-deoxyglucose selectively inhibits Fc and complement receptor-mediated phagocytosis in mouse peritoneal macrophages. J. Exp. Med. 144:1484-1493.
Speert, D. P. and S. Gordon, 1991, Phagocytosis of Unopsonized Pseudomonas aeruginosa by Murine Macrophages is Absolutely Dependent Upon the Presence of Glucose. Abstracts of The 1991 ICAAC.
Speert, D. P. and S. Gordon, 1992. Phagocytosis of Unopsonized Pseudomonas Aeruginosa by Murine Macrophages is a Two-Step Process Requiring Glucose. J. Clin. Investigation. in press.
Barghouthi Sameer
Gordon Siamon
Speert David
Griffin Ronald W.
University of British Columbia
LandOfFree
Factors which regulate macrophage antibacterial activity does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Factors which regulate macrophage antibacterial activity, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Factors which regulate macrophage antibacterial activity will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2181753